中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2011年
3期
217-221
,共5页
赵玲娣%李峻岭%王燕%王彬%王宏羽%郝学志%崔成旭%张湘茹%石远凯
趙玲娣%李峻嶺%王燕%王彬%王宏羽%郝學誌%崔成旭%張湘茹%石遠凱
조령제%리준령%왕연%왕빈%왕굉우%학학지%최성욱%장상여%석원개
癌,非小细胞肺%表皮生长因子受体酪氨酸激酶抑制剂%治疗结果%因素分析,统计学
癌,非小細胞肺%錶皮生長因子受體酪氨痠激酶抑製劑%治療結果%因素分析,統計學
암,비소세포폐%표피생장인자수체락안산격매억제제%치료결과%인소분석,통계학
Carcinoma,non-small cell lung%EGFR-TKI%Treatment outcome%Factor analysis,statistical
目的 探讨影响表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗晚期非小细胞肺癌(NSCLC)患者疗效的临床因素.方法 对2005年1月至2006年12月接受EGFR-TKI治疗的166例晚期NSCLC患者的临床资料进行回顾性分析,其中ⅢB期62例,Ⅳ期104例,均有可测量的临床病灶.结果 166例NSCLC患者中,119例取得临床获益,疾病控制率(DCR)为71.7%.患者的性别、年龄、吸烟情况、病理类型、应用EGFR-TKI时是否存在骨脑转移、应用EGFR-TKI治疗的时机以及诊断时血清乳酸脱氢酶(LDH)水平不影响EGFR-TKI的治疗效果.在126例有血清癌胚抗原(CEA)水平的NSCLC患者中,84例患者CEA高于正常水平,诊断时血清CEA水平高者和正常者的DCR分别为79.8%和59.5%(P=0.016).在临床获益患者中,吸烟状态和诊断时CEA水平影响无进展生存期(PFS),其中不吸烟者的PFS为(9.57±6.75)个月,轻度吸烟者为(4.86±3.44)个月,重度吸烟者为(5.25±4.34)个月(P=0.007);诊断时CEA水平高者的PFS为(9.45±7.48)个月,CEA水平正常者为(6.52±4.46)个月(P=0.036).结论 EGFR-TKI治疗晚期NSCLC是安全有效的,CEA水平高的患者更易从EGFR-TKI治疗中获益.
目的 探討影響錶皮生長因子受體酪氨痠激酶抑製劑(EGFR-TKI)治療晚期非小細胞肺癌(NSCLC)患者療效的臨床因素.方法 對2005年1月至2006年12月接受EGFR-TKI治療的166例晚期NSCLC患者的臨床資料進行迴顧性分析,其中ⅢB期62例,Ⅳ期104例,均有可測量的臨床病竈.結果 166例NSCLC患者中,119例取得臨床穫益,疾病控製率(DCR)為71.7%.患者的性彆、年齡、吸煙情況、病理類型、應用EGFR-TKI時是否存在骨腦轉移、應用EGFR-TKI治療的時機以及診斷時血清乳痠脫氫酶(LDH)水平不影響EGFR-TKI的治療效果.在126例有血清癌胚抗原(CEA)水平的NSCLC患者中,84例患者CEA高于正常水平,診斷時血清CEA水平高者和正常者的DCR分彆為79.8%和59.5%(P=0.016).在臨床穫益患者中,吸煙狀態和診斷時CEA水平影響無進展生存期(PFS),其中不吸煙者的PFS為(9.57±6.75)箇月,輕度吸煙者為(4.86±3.44)箇月,重度吸煙者為(5.25±4.34)箇月(P=0.007);診斷時CEA水平高者的PFS為(9.45±7.48)箇月,CEA水平正常者為(6.52±4.46)箇月(P=0.036).結論 EGFR-TKI治療晚期NSCLC是安全有效的,CEA水平高的患者更易從EGFR-TKI治療中穫益.
목적 탐토영향표피생장인자수체락안산격매억제제(EGFR-TKI)치료만기비소세포폐암(NSCLC)환자료효적림상인소.방법 대2005년1월지2006년12월접수EGFR-TKI치료적166례만기NSCLC환자적림상자료진행회고성분석,기중ⅢB기62례,Ⅳ기104례,균유가측량적림상병조.결과 166례NSCLC환자중,119례취득림상획익,질병공제솔(DCR)위71.7%.환자적성별、년령、흡연정황、병리류형、응용EGFR-TKI시시부존재골뇌전이、응용EGFR-TKI치료적시궤이급진단시혈청유산탈경매(LDH)수평불영향EGFR-TKI적치료효과.재126례유혈청암배항원(CEA)수평적NSCLC환자중,84례환자CEA고우정상수평,진단시혈청CEA수평고자화정상자적DCR분별위79.8%화59.5%(P=0.016).재림상획익환자중,흡연상태화진단시CEA수평영향무진전생존기(PFS),기중불흡연자적PFS위(9.57±6.75)개월,경도흡연자위(4.86±3.44)개월,중도흡연자위(5.25±4.34)개월(P=0.007);진단시CEA수평고자적PFS위(9.45±7.48)개월,CEA수평정상자위(6.52±4.46)개월(P=0.036).결론 EGFR-TKI치료만기NSCLC시안전유효적,CEA수평고적환자경역종EGFR-TKI치료중획익.
Objective To explore the clinical factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer. Methods Clinical data were retrospective analyzed to determine the clinical factors affecting the outcome of 166 patients with advanced non-small cell lung cancer who received EGFR-TKI treatment in our hospttal from January of 2005 to December of 2006. Results One hundred and nineteen patients benefited from EGFR-TKI treatment in the total of 166 patients and the disease control rate was 71.7%. Among the factors analyzed, sex, age, smoking, pathological type, brain and bone metastasis or not when EGFR-TKI was used, the time using EGFR-TKI and the level of LDH at the time of diagnosis had no significant effect on the clinical benefit rate. Among the 126 patients with serum CEA assayed at diagnosis, 84 cases had a higher serum CEA level. Compared with the patients with normal serum CEA level, the patients with a higher serum CEA level benefited more easily from EGFR-TKI therapy, with a disease control rate of 79.8% and 59.5%, respectively (P = 0. 016). Among the patients who got benefits from EGFR-TKI treatment, smoking and the CEA level at diagnosis had effects on the duration of progression-free survival. The progression free survivals were 9.57 ± 6.75 months in non-smokers, 4.86 ±3.44 months in light-smokers and 5.25 ± 4.34 months in heavy-smokers (P = 0.007 ). The progression free survival was 9.45 ± 7.48 months in the group with a higher serum CEA level and 6.52 ± 4.46 months in the group with normal serum CEA level (P = 0.036). Conclusions In patients with advanced non-small cell lung cancer, EGFR-TKIs treatment is safe and effective. The patients with high CEA level are prone to benefit from it.
